# Schedules of Controlled Substances: Diphenidine Added to Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/diphenidine-schedule-i-dea-update-controlled-substance-placement/ > **Published:** 2026-06-19T23:41:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:25:26-04:00 > **Clinical Summary:** Stay informed on the diphenidine schedule i dea update and its placement as a controlled substance under federal law. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation Clinical Summary The Drug Enforcement Administration has placed diphenidine, a synthetic dissociative drug, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, classifying it as having high abuse potential and no currently accepted medical use. While diphenidine itself is not cannabis-related, this regulatory action reflects the ongoing federal approach to controlling novel psychoactive substances that share pharmacological properties with established drugs of abuse. The scheduling decision is based on diphenidine’s structural similarity to phencyclidine (PCP) and its dissociative effects, which pose [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks similar to other controlled dissociatives. For clinicians, this action demonstrates the DEA’s proactive stance in scheduling emerging drugs before they become widespread [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threats, paralleling concerns about novel cannabinoid synthetics that have similarly required emergency scheduling measures. Understanding how the federal government classifies novel psychoactive substances helps clinicians recognize that patients may encounter these unregulated compounds and should be counseled about their unknown risks and legal status. Clinicians should remain vigilant about emerging synthetic drugs in their communities and educate patients that legal availability does not equate to safety or medical legitimacy. Clinical Perspective 🧠 The DEA’s scheduling of diphenidine as a Schedule I controlled substance reflects the ongoing regulatory challenge posed by novel synthetic drugs that emerge faster than formal toxicological data can accumulate. Diphenidine, a dissociative arylcyclohexylamine structurally similar to established drugs like phencyclidine, has limited human safety data but has appeared in forensic and poison control reports with concerning neuropsychiatric effects including agitation, dissociation, and potential for abuse. While emergency scheduling provides a necessary [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) safeguard when emerging threats outpace traditional approval processes, clinicians should recognize that Schedule I designation does not eliminate patient exposure—such compounds continue circulating in unregulated markets and may present in acute care settings with atypical presentations that resemble known dissociative intoxication. The lack of rigorous human studies on diphenidine means that management remains largely supportive and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Policy Watch: 20 Regulatory Updates — June 19, 2026](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update-june-2026/) - [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of Diphenidine in Schedule I Detailed analysis of diphenidine’s classification in Schedule I and its regulatory background. Read More [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Explore the scheduling of MDMB-4en-PINACA and its implications for [controlled substances policy](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/). [Explore Article](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Review the temporary scheduling of 2-Fluorodeschloroketamine and its regulatory context. [Learn More](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).